Anavex Life Sciences remains one of the few non-amyloid Alzheimer's drug developers. Find out why I rate AVXL stock as a Hold ...

December 2024 seems to be the month of skepticism for Biogen Inc ( NASDAQ:BIIB ), as this biotechnology company focusing on neurological and neurodegenerative diseases has received multiple downgrades ...

It’s been a year of big stories about Big Pharmas in the healthcare marketing world. | It’s been a year of big stories about ...

This year saw lofty highs and devastating lows for neuroscience drug developers like Bristol Myers Squibb, Eli Lilly and AbbVie, following the predictable pattern of successes and failures that ...

BMO Capital downgraded Biogen (BIIB) to Market Perform from Outperform with a price target of $164, down from $230. Work is underway at Biogen, ...

Bristol Myers Squibb acquires global rights to BioArctic’s Alzheimer’s antibody candidates BAN1503 and BAN2803 for up to $1.3 ...

Seoul Asan Medical Center said it started prescribing the early Alzheimer's disease drug "Leqembi" (generic name lecanemab) ...

Bristol Myers Squibb has turned to the source of Leqembi to further its push into Alzheimer’s disease, paying BioArctic $100 ...

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that it has entered into a global exclusive license agreement with Bristol ...

China's medical regulator has approved Eli Lilly's treatment for early Alzheimer's, providing patients with another option ...

China is the fourth major market where Kisunla has been approved after the US, Japan, and GB. It gets the green light there ...

China is the fourth major market in which the treatment, sold under the brand name Kisunla, has received approval after the ...